Related Experiment Video
Updated: Feb 11, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
DAAs and long-term clinical outcome in hepatitis C: the panacea for all diseases still does not exist
Alessandro Perrella1,1, Luca Rinaldi1, Alfonso Galeota-Lanza1
1VII Department of Infectious Disease and Immunology, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy. Liver Unit, King's College medical School University, London, UK. Gastroenterology Unit, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. Hepatology Unit, AORN Hospital A. Cardarelli, Naples, Italy. I Division Infectious Disease, Ospedali dei Colli P. O. D. Cotugno, Naples, Italy.
No abstract available in PubMed .
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Kidney Disease II: Clinical Manifestations
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Coronary Artery Disease III: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...

